Cargando…

Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?

We earlier reported that coating poorly water-soluble drugs with nano-hydroxyapatite (nano-HAP) improves bioavailability after oral administration. In the present study, we coated BCS Class IV drug acetazolamide (AZ) with nano-HAP (AZ/HAP formulation), and investigated its bioavailability and nano-H...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneko, Kenichi, Miyasaka, Ryosuke, Hayman, Roslyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119549/
https://www.ncbi.nlm.nih.gov/pubmed/35588130
http://dx.doi.org/10.1371/journal.pone.0268067
_version_ 1784710726306234368
author Kaneko, Kenichi
Miyasaka, Ryosuke
Hayman, Roslyn
author_facet Kaneko, Kenichi
Miyasaka, Ryosuke
Hayman, Roslyn
author_sort Kaneko, Kenichi
collection PubMed
description We earlier reported that coating poorly water-soluble drugs with nano-hydroxyapatite (nano-HAP) improves bioavailability after oral administration. In the present study, we coated BCS Class IV drug acetazolamide (AZ) with nano-HAP (AZ/HAP formulation), and investigated its bioavailability and nano-HAP’s role in promoting it. We tested AZ bioavailability after a single oral dose of the AZ/HAP formulation in rats, followed by a series of in vitro, ex vivo and in vivo testing. The binding state of AZ and nano-HAP was analyzed by gel filtration chromatography. AZ permeability was studied using a Caco-2 cell monolayer assay kit, to test for tight junction penetration, then using an Ussing chamber mounted with intestinal epithelium, both with and without Peyer’s patch tissue, to examine the role of intracellular transport. Fluorescence-labeled nano-HAP particles were administered orally in rats to investigate their localization in the intestinal tract. The area under the blood concentration time-curve in rats was about 4 times higher in the AZ/HAP formulation group than in the untreated AZ group. Gel filtration analysis showed AZ and nano-HAP were not bound. The Caco-2 study showed equivalent AZ permeability for both groups, but without significant change in transepithelial electrical resistance (TEER), indicating that tight junctions were not penetrated. In the Ussing chamber study, no significant difference in AZ permeability between the two groups was observed for epithelium containing Peyer’s patch tissue, but for epithelium without Peyer’s patch tissue, at high concentration, significantly higher permeability in the AZ/HAP formulation group was observed. Fluorescent labeling showed nano-HAP particles were present in both intestinal villi and Peyer’s patch tissue 30 min after oral administration. Our results suggest that nano-HAP’s enhancement of drug permeability from the small intestine occurs not via tight junctions, but intracellularly, via the intestinal villi. Further study to elucidate the mechanism of this permeability enhancement is required.
format Online
Article
Text
id pubmed-9119549
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91195492022-05-20 Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how? Kaneko, Kenichi Miyasaka, Ryosuke Hayman, Roslyn PLoS One Research Article We earlier reported that coating poorly water-soluble drugs with nano-hydroxyapatite (nano-HAP) improves bioavailability after oral administration. In the present study, we coated BCS Class IV drug acetazolamide (AZ) with nano-HAP (AZ/HAP formulation), and investigated its bioavailability and nano-HAP’s role in promoting it. We tested AZ bioavailability after a single oral dose of the AZ/HAP formulation in rats, followed by a series of in vitro, ex vivo and in vivo testing. The binding state of AZ and nano-HAP was analyzed by gel filtration chromatography. AZ permeability was studied using a Caco-2 cell monolayer assay kit, to test for tight junction penetration, then using an Ussing chamber mounted with intestinal epithelium, both with and without Peyer’s patch tissue, to examine the role of intracellular transport. Fluorescence-labeled nano-HAP particles were administered orally in rats to investigate their localization in the intestinal tract. The area under the blood concentration time-curve in rats was about 4 times higher in the AZ/HAP formulation group than in the untreated AZ group. Gel filtration analysis showed AZ and nano-HAP were not bound. The Caco-2 study showed equivalent AZ permeability for both groups, but without significant change in transepithelial electrical resistance (TEER), indicating that tight junctions were not penetrated. In the Ussing chamber study, no significant difference in AZ permeability between the two groups was observed for epithelium containing Peyer’s patch tissue, but for epithelium without Peyer’s patch tissue, at high concentration, significantly higher permeability in the AZ/HAP formulation group was observed. Fluorescent labeling showed nano-HAP particles were present in both intestinal villi and Peyer’s patch tissue 30 min after oral administration. Our results suggest that nano-HAP’s enhancement of drug permeability from the small intestine occurs not via tight junctions, but intracellularly, via the intestinal villi. Further study to elucidate the mechanism of this permeability enhancement is required. Public Library of Science 2022-05-19 /pmc/articles/PMC9119549/ /pubmed/35588130 http://dx.doi.org/10.1371/journal.pone.0268067 Text en © 2022 Kaneko et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kaneko, Kenichi
Miyasaka, Ryosuke
Hayman, Roslyn
Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?
title Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?
title_full Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?
title_fullStr Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?
title_full_unstemmed Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?
title_short Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?
title_sort nano-hydroxyapatite improves intestinal absorption of acetazolamide (bcs class iv drug)–but how?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119549/
https://www.ncbi.nlm.nih.gov/pubmed/35588130
http://dx.doi.org/10.1371/journal.pone.0268067
work_keys_str_mv AT kanekokenichi nanohydroxyapatiteimprovesintestinalabsorptionofacetazolamidebcsclassivdrugbuthow
AT miyasakaryosuke nanohydroxyapatiteimprovesintestinalabsorptionofacetazolamidebcsclassivdrugbuthow
AT haymanroslyn nanohydroxyapatiteimprovesintestinalabsorptionofacetazolamidebcsclassivdrugbuthow